This is a case report of a 25-year-old male patient who had a widespread petechial rash, oral bleeding, and thrombocytopenia three days after receiving the booster COVID-19 vaccination dose.Ī 25-year-old healthy Asian male presented to the hospital after three days of receiving the Pfizer-BioNTech BNT16B2b2 mRNA vaccine. As a result of the administration of SARS-CoV-2 vaccinations, a few incidences of immune thrombocytopenic purpura (ITP) have been documented. Only a few patients experienced serious adverse effects that need aggressive care or even hospitalization. After the second dose of the vaccination, chills, low-grade fever, malaise, headache, and myalgia were more prevalent. In the vaccine's clinical trials, side effects occurred within seven days following vaccination, however, the degree of these side effects was mainly mild to moderate. Everyone else should receive the booster dose six months after the second dose. People taking chemotherapy, organ transplant recipients, untreated HIV infection, post stem transplant, and active treatment with glucocorticoids are included in this group, according to the Centers for Disease Control and Prevention (CDC). A booster (third) dose is now suggested for moderate to severely immunocompromised persons four weeks following the second dose of vaccine. The Pfizer-BioNTech BNT16B2b2 mRNA vaccination is advised to be given in two doses, three weeks apart. Since December 2020, the Pfizer-BioNTech BNT16B2b2 mRNA vaccine has been widely used to prevent COVID-19 infection. This necessitated the immediate availability of COVID-19 vaccines. For billions of people throughout the world, COVID-19 has been a nightmare, incurring devastating economic, physical, and psychological losses. In this article, we present the patient's case and review the existing literature on vaccine-induced immune thrombocytopenia.ĬOVID-19, SARS-CoV-2, Rash, Bleeding, Thrombocytopenia, VaccineĬoronavirus disease (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused significant damage and challenges globally. Based on the existing literature and the absence of any other triggering factors, immune thrombocytopenia caused by the booster dose of Pfizer-BioNTech BNT16B2b2 mRNA vaccine was diagnosed. We discuss the case of a 25-year-old gentleman who received an uneventful first and second vaccination doses but experienced widespread petechial rash, oral bleeding, and thrombocytopenia within three days of receiving the booster dose. One of the documented adverse effects of the COVID-19 immunizations is vaccine-induced immune thrombocytopenic purpura.
Except for mild and infrequent adverse effects, almost all vaccinations are considered safe. Vaccination is now widely regarded as the most effective way to reduce the pandemic's morbidity and death.
0 kommentar(er)
